Literature DB >> 17164994

Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts.

Goukei Shu1, Kaname Yamamoto, Masakazu Nagashima.   

Abstract

Patients with rheumatoid arthritis commonly suffer both systemic and periarticular osteoporosis. Bisphosphonates (BPs) are inhibitors of bone resorption, and several derivatives have been developed for treatment of enhanced bone resorption. We aimed to characterize osteoclast formation in two different sites, the proximal tibial and distal tibial areas, in rats with adjuvant arthritis, and to investigate the impact of amino or non-amino types of bisphosphonate. Adjuvant arthritis was initiated in rats while administering daily injections of either etidronate, a non-amino BP, or alendronate, an amino BP, for 3 weeks. On the day following the last injection, bone mineral density (BMD) was measured in the proximal tibia to assess systemic osteoporosis and in the distal tibia for periarticular osteoporosis using dual-energy X-ray absorptiometry. Subsequently, bone marrow cells from either end of the tibia were collected and incubated for 7 days before staining and counting tartrate-resistant acid phosphatase positive cells. In the rats with adjuvant arthritis, BMD of either end of the tibia was lower than in normal rats. Although etidronate prevented bone mineral loss at both ends, distal loss was significantly less than proximal. In contrast, alendronate significantly inhibited mineral loss primarily in the proximal area. Large osteoclasts, defined as having five or more nuclei, formed preferentially in the proximal tibia, while small osteoclasts with fewer than four nuclei were found mainly distally. The suppressive effect of alendronate was greater on the large osteoclasts, while etidronate had a greater effect on the small osteoclasts. These results show that the size and multinuclearity of osteoclasts and the number of osteoclasts formed are different in the distal and proximal areas of the tibia, and that alendronate and etidronate may suppress different types of osteoclasts as discriminated by the number of nuclei.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164994     DOI: 10.1007/s10165-006-0515-1

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  5 in total

Review 1.  Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.

Authors:  Shi Wei; Gene P Siegal
Journal:  Pathol Res Pract       Date:  2008-08-30       Impact factor: 3.250

2.  Osteoprotegerin disrupts peripheral adhesive structures of osteoclasts by modulating Pyk2 and Src activities.

Authors:  Hongyan Zhao; Xuezhong Liu; Hui Zou; Nannan Dai; Lulian Yao; Xiao Zhang; Qian Gao; Wei Liu; Jianhong Gu; Yan Yuan; Jianchun Bian; Zongping Liu
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

3.  Influence of bisphosphonate treatment on medullary macrophages and osteoclasts: an experimental study.

Authors:  Natalia Daniela Escudero; Patricia Mónica Mandalunis
Journal:  Bone Marrow Res       Date:  2012-09-13

4.  Changes in microarchitectural characteristics at the tibial epiphysis induced by collagen-induced rheumatoid arthritis over time.

Authors:  Joo Hyung Lee; Keyoung Jin Chun; Han Sung Kim; Sang Ho Kim; Kwon-Yong Lee; Dae Jun Kim; Dohyung Lim
Journal:  Clin Interv Aging       Date:  2012-09-18       Impact factor: 4.458

5.  Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis.

Authors:  Letizia Penolazzi; Ilaria Lampronti; Monica Borgatti; Mahmud Tareq Hassan Khan; Margherita Zennaro; Roberta Piva; Roberto Gambari
Journal:  BMC Complement Altern Med       Date:  2008-10-30       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.